Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

3 numbers show human-in-the-loop cyber defence is outdated
How do you defend against AI attack speed? As cyberattacks become increasingly AI-driven, human-in-the-loop cyber defence is leaving organisations vul
The Future of Trusteeship: In Good Hands?
In this episode of the Pensions Perspectives Podcast, host Luna Fadayel is joined by David Walmsley of ?@ThePensionsRegulator?, Jenny Gibbons (Governa
Stewardship reporting under the new LGPS regime
"If the pool is a Stewardship Code signatory, do funds still need to report?" The recent pooling reforms change how investment strategy is implemented

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.